Indivior wary of rivals launching copycat products after US court denies appeal to keep ban in place

Writer, Stock Market Wire
Tuesday, February 12, 2019 - 07:45

Indivior said Tuesday a U.S. court had denied its appeal against a decision that would lift the ban preventing rival Dr. Reddy's Laboratories from selling a generic version of the company's opioid addiction treatment.

Indivior said it would file an emergency request to keep the ban in place pending resolution of its forthcoming application for an administrative stay to the Supreme Court of the United States.

The U.S. Court of Appeals for the Federal Circuit had denied Indivior's appeal on February 11, and ordered that the rival Dr. Reddy's Laboratories be granted the right to sell a generic version of the company's opioid treatment on February 19, 2019.

'After the mandate issues, Dr. Reddy's Laboratories and Alvogen Pine Brook will no longer be prevented from selling, offering to sell, or importing their generic buprenorphine/naloxone sublingual film product,' Indivior said.


Related content

Reckitt Benckiser responds to US indictment of Indivior

Reckitt Benckiser Group confirmed that it had set aside a provision for legal costs related to Indivior, a former unit of the company.

Reckitt Benckiser...

Wed, 10/04/2019 - 13:12


Indivior faces series of charges over fraudulent activity in US

Indivior was charged by US authorities over a series of criminal offences including mail, wire and health fraud. The company denied the allegations, citing they...

Wed, 10/04/2019 - 08:03


Indivior presents data to help tackle opioid abuse

Indivior presented data over the weekend to help the healthcare community and others understand the challenges faced by patients with opioid use disorder and potential...

Mon, 08/04/2019 - 07:57


Indivior presents opioid addiction treatment study findings at Florida gathering

Indivior said it had presented data from two studies evaluating efficacy and long-term safety of a once-monthly injection of a treatment of moderate-to-severe opioid use...

Fri, 05/04/2019 - 13:45


Indivior launches injectable schizophrenia treatment in US

Indivior said it had launched in the US a new injectable treatment for schizophrenia.

The once-monthly treatment, Perseris, used an extended-release delivery system to form...

Wed, 27/02/2019 - 13:18